New data from the European Society of Cardiology Congress show that bempedoic acid reduced total events and that mavacamten’s safety and efficacy continued through 56 weeks.
STRENGTH Results Prompt Questions About Omega-3 and Cardiovascular Risk
Detailed findings from this large outcomes study of omega-3 carboxylic acid have renewed scrutiny over potential confounding effects of the mineral oil placebo used in the earlier REDUCE-IT trial.
Reigniting Clinical Research in the Wake of a Pandemic
We were recruiting patients for 75+ cardiovascular clinical trials when COVID-19 struck. Here’s how we’ve worked to keep as many of them on track as possible.
Advice for Getting a Start (or Upping Your Game) in Clinical Research
A veteran physician researcher shares tips on getting started in clinical trials, obtaining funding, following regulatory standards and making your research efforts a success.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Genetic Analysis of Evacetrapib Outcomes Fails to Confirm Findings with Dalcetrapib
A genotype found to be associated with reduced cardiovascular events in a study of dalcetrapib wasn’t associated with benefit in a trial of fellow CETP inhibitor evacetrapib.
PRECISION-ABPM Reveals Differential Blood Pressure Effects with Chronic Use of 3 NSAIDs
This substudy of the huge PRECISION trial shows that clinicians need to weigh the potential dangers of worsened blood pressure control when considering chronic use of NSAIDs — especially ibuprofen.
CETP Inhibitor Evacetrapib’s Disappointments Extend to Diabetics Too
The ACCELERATE trial found no effect on cardiac events with evacetrapib despite large HDL gains and solid LDL declines. A substudy presented at ESC 2017 now shows the drug fared no better when analysis was limited to diabetic patients.
New PARTNER 2A Insights: Worsened RV Function and Tricuspid Regurgitation More Common with SAVR Vs. TAVR
The transcatheter approach to aortic valve replacement in intermediate-risk patients appears to curb the risk of these potentially deadly effects, new subanalyses presented at ACC.17 show.
Get These Presentations into Your ACC.17 Itinerary
Make room in your schedule at the American College of Cardiology meeting for key presentations ranging from the SPIRE 1 and 2 trials to ABSORB III two-year results and more.
MILANO-PILOT Brings ApoA-1 Milano Hopes to an End
Long-standing hope for MDCO-216, which contains the ApoA-1 Milano variant of HDL, disappears as the compound fails to yield coronary plaque regression. But the jury’s still out on other HDL-targeted therapies.